Breast Implant Lawsuit 2026: MDL 2921 Status, Case Data, and What to Do Next

As of July 2026, the breast implant lawsuit against Allergan is consolidated in MDL No. 2921 in the U.S. District Court for the District of New Jersey, with roughly 1,488 federal cases pending and no global settlement reached. The litigation centers on Allergan's BIOCELL textured breast implants, which the FDA linked to a rare cancer called BIA-ALCL and recalled in July 2019. The first bellwether trial is scheduled for October 19, 2026, and its outcome is expected to shape any future breast implant settlement.

●       The Allergan breast implant lawsuit is consolidated as MDL No. 2921 in the U.S. District Court for the District of New Jersey, before Judge Brian R. Martinotti (docket no. 2:19-md-02921(BRM)(LDW)).

●       Approximately 1,488 cases were pending in the MDL as of June 2026, an increase of roughly 18% from January 2025, according to litigation trackers reviewing the federal docket.

●       The FDA ordered a worldwide recall of Allergan's textured BIOCELL breast implants and tissue expanders in July 2019 after finding a substantially elevated risk of BIA-ALCL, a rare lymphoma of the immune system.

●       FDA data reviewed through June 30, 2024 lists 1,380 BIA-ALCL cases and 64 deaths tracked since the agency began monitoring the condition in 2011.

●       No breast implant settlement has been finalized. The first bellwether trial is set for October 19, 2026, and a Qualified Settlement Fund was established under Case Management Order No. 38 in December 2025 to handle future fund administration.

●       Women with a recalled textured implant, a BIA-ALCL diagnosis, or implant-related complications may qualify to file breast implant injury claims, but state statutes of limitations apply, so prompt consultation with a breast implant attorney is advisable.

The current breast implant lawsuit refers to product liability litigation filed against Allergan (an AbbVie company) over its Natrelle BIOCELL textured breast implants and tissue expanders. Plaintiffs allege Allergan knew or should have known of an elevated cancer risk tied to the textured surface of these devices and failed to adequately warn patients and surgeons.

Federal cases were centralized on December 18, 2019, when the Judicial Panel on Multidistrict Litigation created MDL No. 2921, In re: Allergan BIOCELL Textured Breast Implant Products Liability Litigation, in the U.S. District Court for the District of New Jersey. The docket is overseen by Judge Brian R. Martinotti, with Magistrate Judge Leda Dunn Wettre managing pretrial discovery.

The MDL is split into two tracks: claims involving a confirmed diagnosis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), and separate non-cancer claims from patients alleging systemic injury or complications from the textured device itself, including those who still have the implant in place.

In July 2019, the FDA requested that Allergan voluntarily recall all of its BIOCELL textured breast implants and tissue expanders after agency data showed a disproportionately higher rate of BIA-ALCL associated with these textured-surface products compared to smooth-surface implants from other manufacturers. Allergan complied, issuing a worldwide recall of its Natrelle BIOCELL saline-filled implants, one BIOCELL silicone gel-filled implant line, and BIOCELL tissue expanders.

The FDA classified this as a Class I recall, its most serious category, reserved for situations where continued use of a device could cause serious injury or death. Legal trackers estimate the recall affected more than four million devices distributed worldwide, though the FDA has not published a single verified global unit count; that figure should be treated as an industry estimate rather than a confirmed agency total.

According to FDA adverse event data, Allergan-manufactured implants accounted for approximately 86% of BIA-ALCL cases reported to the agency in which the manufacturer was identified, which is the core factual basis underlying the textured breast implant lawsuit and the associated breast implant recall lawsuit claims.

Breast Implant-Associated Anaplastic Large Cell Lymphoma, or BIA-ALCL, is a cancer of the immune system, specifically a T-cell lymphoma that develops in the scar tissue and fluid surrounding a breast implant. It is not a form of breast cancer, and the FDA has found no association between BIA-ALCL and the implant's fill material (saline versus silicone).

The FDA has tracked BIA-ALCL cases since 2011. Medical device reports reviewed through June 30, 2024 identify 1,380 cases and 64 deaths in the United States, according to data compiled by the Breast Implant Safety Alliance from FDA sources. This figure has grown substantially over time: the FDA's August 20, 2020 safety update counted 733 unique cases and 36 deaths worldwide, itself an increase of 160 cases and 3 deaths from the 573 cases and 33 deaths reported in July 2019, around the time of the recall.

Medical literature cited by the FDA estimates the lifetime risk of developing BIA-ALCL for women with textured implants at between 1 in 3,817 and 1 in 30,000. The median time from implant placement to diagnosis is approximately 8 to 9 years, with a reported range extending beyond 20 years in some cases.

Most BIA-ALCL cases, roughly 80%, are diagnosed at an early stage and are treatable through surgical removal of the implant and surrounding capsule. The FDA does not recommend prophylactic (preventive) removal of textured implants in patients without symptoms; this is general regulatory guidance and not personalized medical advice.

This section reflects the most current, publicly available docket information as of July 23, 2026.

Current Status, Date-Stamped

●       December 18, 2019: The Judicial Panel on Multidistrict Litigation establishes MDL No. 2921 in the District of New Jersey.

●       September 25, 2025: Case Management Order No. 36 identifies approximately 350 "Product-in-Place" plaintiffs, meaning claimants without a BIA-ALCL diagnosis or explant surgery, and sets a 15% sample discovery protocol using short-form fact sheets.

●       October 14, 2025: Case Management Order No. 37 sets the first surgical explant bellwether trial for October 19, 2026, structured as a single-plaintiff trial, with the specific plaintiff to be selected by the court by June 30, 2026.

●       December 24, 2025: Case Management Order No. 38 establishes a Qualified Settlement Fund (QSF) and appoints fund administrators, a procedural mechanism courts use to manage and disburse money tied to resolved claims. This step is administrative and does not, by itself, confirm a global settlement has been reached.

●       June 2026: Docket trackers report approximately 1,488 pending federal cases, an increase of about 18% since January 2025; a separate tracker citing an earlier snapshot in early 2026 reported more than 1,200 pending cases.

●       As of today, July 23, 2026: The case remains in active pretrial discovery. No global settlement has been announced, and the October 19, 2026 bellwether trial has not yet occurred.

Exact, court-confirmed figures for total dollar exposure, total plaintiffs (as opposed to pending federal cases), or a settlement matrix have not been publicly disclosed as of this writing. Readers should treat any specific compensation figures circulating online with caution unless they cite a specific, dated court filing.

No. As of July 2026, there is no global or master breast implant settlement in the Allergan BIOCELL MDL. Legal trackers monitoring the docket report that both sides remain in discovery, and that the results of the October 19, 2026 bellwether trial are expected to inform any future settlement negotiations rather than the reverse.

The December 2025 establishment of a Qualified Settlement Fund under Case Management Order No. 38 is a notable procedural development, since courts typically set up such funds in anticipation of resolving at least a subset of claims, but it does not itself constitute a confirmed settlement amount or timeline.

It is worth distinguishing the current litigation from the much larger silicone gel breast implant litigation of the 1990s, which involved different manufacturers, different alleged injuries (autoimmune and connective tissue disease claims, since largely unsupported by subsequent research), and a different legal process.

In March 1994, implant manufacturers proposed a global class settlement following Dow Corning's Chapter 11 bankruptcy filing. Sources describe the fund size differently depending on the accounting basis and date: a federal appellate decision describes a proposed $4.225 billion global settlement approved by the MDL court in 1994, a Health Affairs analysis cites a $4.25 billion fund, and the American Medical Association's Journal of Ethics describes a $3.4 billion settlement accepted by more than 90% of class members. That original settlement later collapsed when roughly 400,000 women filed claims, far exceeding what the fund could pay.

Dow Corning itself filed for bankruptcy protection in 1995. Under its eventual bankruptcy reorganization plan, which took effect June 1, 2004, the company funded a separate settlement trust; contemporaneous news reporting cited figures ranging from a $3.2 billion offer announced in 1998 to a $2.35 billion fund described at the time the company emerged from bankruptcy in 2004, with roughly 170,000 breast implant claimants and 75,000 other silicone-implant claimants eligible to file. These are historical figures from a distinct, decades-old case and are not predictive of outcomes in the current BIA-ALCL litigation.

The following is general information, not personalized legal advice. Eligibility depends on facts specific to each person's medical and implant history, and only a licensed attorney reviewing your records can confirm whether you qualify.

Based on the categories currently recognized in MDL No. 2921, you may want to have your case evaluated if any of the following apply:

●       You received an Allergan Natrelle or McGhan BIOCELL textured breast implant or tissue expander, for cosmetic augmentation, reconstruction, or revision surgery.

●       You have a confirmed diagnosis of BIA-ALCL, generally established through CD30 immunohistochemistry (IHC) testing of fluid or tissue around the implant.

●       You had your implant removed (explanted) due to complications potentially linked to the textured surface, such as capsular contracture, rupture, persistent seroma, or a capsular mass.

●       You currently still have a recalled textured implant in place, even without symptoms or a diagnosis; this is the "Product-in-Place" category currently active in the MDL.

If you are unsure whether your implant was textured or smooth, many patients do not know this detail offhand. You can typically confirm it by requesting your operative report from the implanting surgeon, checking any device identification card provided at the time of surgery, or contacting the surgical facility's medical records department.

What Breast Implant Compensation Might Be Available?

If you have, or believe you may have, a recalled Allergan BIOCELL textured breast implant, the following general steps can help you understand your situation. This is educational information, not a substitute for individualized legal or medical advice.

●       Confirm your implant type. Request your operative notes, implant device card, or surgical records from your surgeon or the facility where the procedure was performed.

●       Get evaluated for symptoms. Persistent swelling, fluid buildup (seroma), a lump, or a capsular mass developing more than a year after implantation should be evaluated promptly, and CD30 IHC testing can help rule in or out BIA-ALCL.

●       Report complications to the FDA. Adverse events tied to a medical device can be reported through the FDA's MedWatch voluntary reporting program, which feeds the same data used to track BIA-ALCL nationally.

●       Preserve your documentation. Keep surgical records, implant identification stickers or cards, pathology reports, and any correspondence with your surgeon or the manufacturer.

●       Consult a breast implant attorney. Many law firms handling breast implant injury claims offer free, no-obligation case reviews to help determine whether you may be eligible to file, and to explain the filing deadline (statute of limitations) that applies in your state.

●       Do not remove implants solely to join a lawsuit. The FDA does not recommend removing asymptomatic implants as a preventive measure; any explant decision should be made with your physician based on your own medical situation.

The breast implant lawsuit refers to product liability litigation against Allergan over its BIOCELL textured breast implants and tissue expanders. Plaintiffs allege the company knew of an elevated risk of BIA-ALCL, a rare lymphoma, and failed to adequately warn patients before the FDA-requested recall in July 2019. The claims are consolidated in MDL No. 2921 in the U.S. District Court for the District of New Jersey.

Yes. The July 2019 Class I recall of Allergan's BIOCELL textured breast implants and tissue expanders remains in effect; the products were not returned to the market. Litigation over injuries allegedly caused by the recalled devices remains active in MDL No. 2921 as of July 2026, with the first bellwether trial scheduled for October 19, 2026.

No global settlement has been reached as of July 2026. A Qualified Settlement Fund was established under Case Management Order No. 38 in December 2025 to handle future fund administration, but this is a procedural step, not a confirmed settlement amount. Legal trackers expect the October 19, 2026 bellwether trial results to inform future settlement negotiations.

BIA-ALCL, or Breast Implant-Associated Anaplastic Large Cell Lymphoma, is a cancer of the immune system that can develop in the tissue surrounding a breast implant, most often one with a textured surface. It is not breast cancer. The FDA has tracked 1,380 cases and 64 deaths since 2011, based on data reviewed through June 30, 2024.

There is no confirmed average settlement value because no global settlement currently exists in this litigation. Compensation, if a case settles or wins at trial, would typically depend on factors such as diagnosis severity, medical expenses, and lost income, and any figure quoted online without a citation to a specific court filing should be treated as unverified.

You are not legally required to hire an attorney, but mass tort litigation like MDL No. 2921 involves complex procedural rules, deadlines, and evidentiary requirements. Most breast implant attorneys handling these injury claims offer free initial case reviews, which can help you understand whether you may be eligible and what deadlines apply to you.

Deadlines, known as statutes of limitations, vary by state and generally begin running from the date of diagnosis or discovery of the injury rather than the date of the original implant surgery. Because these deadlines differ and are strictly enforced, anyone considering a claim should confirm their specific deadline with a licensed attorney as soon as possible.